Stockscreener 앱 받기
0.45
19.21%
-0.107
전일 마감가:
$0.557
열려 있는:
$0.5723
하루 거래량:
182.50K
Relative Volume:
3.09
시가총액:
$18.73M
수익:
-
순이익/손실:
$-74.56M
주가수익비율:
-0.2457
EPS:
-1.8316
순현금흐름:
$-60.27M
1주 성능:
-29.70%
1개월 성능:
-37.47%
6개월 성능:
-59.46%
1년 성능:
-71.52%
1일 변동 폭
$0.4301
$0.6325
1주일 범위
$0.4301
$0.71
52주 변동 폭
$0.4301
$3.46
Rallybio Corp Stock (RLYB) Company Profile
명칭
Rallybio Corp
전화
203- 859-3820
주소
234 CHURCH STREET, NEW HAVEN
RLYB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.45 | 18.73M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-17 | 개시 | H.C. Wainwright | Buy |
| 2023-04-10 | 개시 | Wedbush | Outperform |
| 2022-12-09 | 개시 | JP Morgan | Overweight |
| 2022-02-22 | 개시 | JMP Securities | Mkt Outperform |
| 2021-08-23 | 개시 | Cowen | Outperform |
| 2021-08-23 | 개시 | Evercore ISI | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
모두보기
Rallybio Corp 주식(RLYB)의 최신 뉴스
Rallybio stock plunges to 52-week low, hitting $0.6 - Investing.com India
Rallybio stock plunges to 52-week low, hitting $0.6 By Investing.com - Investing.com Canada
Rallybio stock plunges to 52-week low at $0.62 amid market challenges - Investing.com Canada
Rallybio stock plunges to 52-week low at $0.62 amid market challenges By Investing.com - Investing.com South Africa
HC Wainwright Issues Positive Estimate for Rallybio Earnings - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Rallybio (NASDAQ:RLYB) Receives “Buy” Rating from HC Wainwright - Defense World
Rallybio’s Promising Developments and Financial Stability Justify Buy Rating - TipRanks
Rallybio Corporation (NASDAQ:RLYB) Is Expected To Breakeven In The Near Future - Simply Wall St
Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating - TipRanks
Rallybio Corporation Reports 2024 Financial Results and Progress - TipRanks
Rallybio revises common stock offering to $9.55 million By Investing.com - Investing.com Australia
Rallybio revises common stock offering to $9.55 million - Investing.com
Rallybio earnings beat by $0.55, revenue fell short of estimates - Investing.com UK
Rallybio Corp SEC 10-K Report - TradingView
Promising Developments and Financial Stability Support Buy Rating for Rallybio - TipRanks
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - BioSpace
Rallybio reports Q4 EPS (25c), consensus (30c) - TipRanks
Rallybio stock plunges to 52-week low of $0.66 By Investing.com - Investing.com Australia
Rallybio stock plunges to 52-week low of $0.66 - Investing.com
Rallybio (RLYB) to Release Quarterly Earnings on Tuesday - Defense World
Rallybio stock hits 52-week low at $0.68 amid market challenges - Investing.com Australia
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
New Haven-based biotech Rallybio faces delisting from Nasdaq - Hartford Business Journal
Rallybio faces Nasdaq delisting over share price woes - Investing.com India
Rallybio faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa
Can Rallybio's Rare Disease Innovations Impress Investors at the TD Cowen Conference? - StockTitan
Rallybio stock plunges to 52-week low at $0.72 amid market challenges - Investing.com Nigeria
Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe - MSN
Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World
Rallybio stock plunges to 52-week low of $0.73 amid market challenges - MSN
Rallybio begins Phase 2 trial for FNAIT prevention therapy - MSN
Rallybio begins Phase 2 trial for FNAIT prevention therapy By Investing.com - Investing.com Nigeria
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - BioSpace
Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Jane Street Group LLC Has $26,000 Holdings in Rallybio Co. (NASDAQ:RLYB) - Defense World
Rallybio Corp (RLYB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):